Loading...
XNAS
NSPR
Market cap79mUSD
Dec 05, Last price  
1.88USD
1D
-2.08%
1Q
-22.31%
Jan 2017
-100.00%
IPO
-100.00%
Name

InspireMD Inc

Chart & Performance

D1W1MN
XNAS:NSPR chart
P/E
—
P/S
11.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
213.11%
Rev. gr., 5y
13.50%
Revenues
7m
+12.96%
006,004,0005,349,0004,873,0002,818,0002,310,0001,894,0002,761,0003,601,0003,721,0002,485,0004,495,0005,171,0006,205,0007,009,000
Net income
-32m
L+60.70%
-3,825-23,976-14,665,000-17,597,000-29,258,000-25,095,000-15,585,000-8,461,000-8,438,000-7,240,000-10,040,000-10,544,000-14,918,000-18,491,000-19,916,000-32,005,000
CFO
-22m
L+33.54%
-825-18,981-6,003,000-8,580,000-10,300,000-19,362,000-11,596,000-7,495,000-8,131,000-7,606,000-9,810,000-9,081,000-13,210,000-15,542,000-16,376,000-21,868,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
URL
https://www.inspiremd.com/en/
IPO date
Apr 12, 2013
Employees
55
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT